- Strategic acquisition of UG 100 sequencer enhances NeoGenomics' (NEO, Financial) diagnostic capabilities.
- New platform enables cost-effective whole genome sequencing with high accuracy.
- Technology allows detection from as little as 2 nanograms of DNA, improving efficiency.
NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions, has announced a collaboration with Ultima Genomics, Inc. to advance cancer diagnostic capabilities using the UG 100 sequencing platform. The alliance aims to leverage Ultima's ppmSeqâ„¢ technology to enhance precision in clinical tests with a focus on early cancer detection.
As part of this strategic collaboration, NeoGenomics has purchased the UG 100 sequencer, which will be installed at their innovation center in Cambridge, UK. The UG 100 is engineered to provide cost-effective and low-error sequencing, a critical advancement for tests such as liquid biopsies and minimal residual disease (MRD) detection. The technology boasts a 5x yield improvement allowing for 30X coverage from merely 2 nanograms of DNA, a significant step forward for detecting rare genetic variants.
With the UG 100 platform, NeoGenomics is positioned to explore fast-growing markets in oncology diagnostics, particularly MRD testing and emerging whole genome sequencing applications. The partnership underscores NeoGenomics' commitment to driving innovation in precision oncology testing, enhancing its competitive positioning in the high-growth segments of cancer care.
"This collaboration with Ultima, a pioneer in cost-efficient sequencing, equips our R&D team with resources to rapidly and efficiently translate innovation for patient care," stated Tony Zook, CEO of NeoGenomics. The integration of the UG 100 into their operations is intended to strengthen NeoGenomics' capacity to provide cutting-edge solutions in oncology diagnostics.
